Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, daptomycin (Cubicin®) cannot be endorsed for use within NHS Wales for the treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with cSSTI. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | daptomycin (Cubicin®) | |
| Formulation | 350 mg and 500 mg powder for solution of injection/infusion | |
| Reference number | 3721 | |
| Indication | Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with cSSTI. |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 20/04/2018 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||